SFX by Ex Libris Inc.

Title:	Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult
Source:	Blood [0006-4971] Morris, Emma yr:2017

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Echevarria, L. "X chromosome inactivation in female patients with Fabry disease." Clinical genetics 89.1 (2015): 44-54.
description	2.	Hacein-Bey Abina, S. "Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome." JAMA: the Journal of the American Medical Association 313.15 (2015): 1550-63.
description	3.	Myers, Alan L. "Clarifying Busulfan Metabolism and Drug Interactions to Support New Therapeutic Drug Monitoring Strategies: A Comprehensive Review." Expert opinion on drug metabolism & toxicology. 13.9: 901-923.
description	4.	Kohn, Donald B. "New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing." Journal of Allergy and Clinical Immunology 139.3 (2017): 726-732.
description	5.	Morgan, Claire P. "Complement therapeutics; history and current progress." Molecular immunology 40.2-4 (2003): 159-170.
description	6.	Elliott, Vimal M. "Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease." Heart 101.12 (2015): 961-6.
description	7.	Scian, M. "The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins." Archives of biochemistry and biophysics 583 (2015): 96-104.
description	8.	Sasahara, Y. "WASP-WIP complex in the molecular pathogenesis of Wiskott-Aldrich syndrome." Pediatrics international 58.1 (2016): 4-7.
description	9.	Weisser, M. "Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions." Journal of Allergy and Clinical Immunology 138.1 (2016): 219-4294967295.
description	10.	"Infectious Diseases." Obesity, Fitness & Wellness Week (2012): 432-.
description	11.	Kaufmann, Kerstin B. "Gene therapy for chronic granulomatous disease: current status and future perspectives." Current gene therapy 14.6 (2014): 447-60.
description	12.	Liao, H. "Stem cell, CRISPR and HIV." Cell cycle 14.13 (2015): 1-2.
description	13.	Cicalese, Maria P. "Clinical applications of gene therapy for primary immunodeficiencies." Human gene therapy 26.4 (2015): 210-9.
description	14.	Politei, J. "Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations - different outcome?" Clinical genetics 89.1 (2015): 88-92.
description	15.	Fledelius, Ulla C. "Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement." Acta ophthalmologica 93.3 (2015): 258-64.
description	16.	Ellaway, C. "Diagnostic dilemma and delay in Fabry disease: Insights from a case series of young female patients." Journal of paediatrics and child health 51.4 (2014): 369-72.
description	17.	Montini, C. "Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo." Molecular therapy 22.4 (2014): 774-785.
description	18.	Booth, C. "Gene therapy for primary immunodeficiency." Current opinion in pediatrics 23.6 (2011): 659-666.
description	19.	Merten, O. "Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application." Human gene therapy 22.3 (2011): 343-356.
description	20.	SALONEN, J. "SERUM COPPER AND THE RISK OF ACUTE MYOCARDIAL-INFARCTION - A PROSPECTIVE POPULATION STUDY IN MEN IN EASTERN FINLAND." American Journal of Epidemiology 134.3 (1991): 268-276.